knowledge -WSS

knowledge

author：explore 2025-09-02 22:24:21 - browse：1313

Adobe

Akili Interactive, which in 2020 made waves by receiving Food and Drug Administration clearance for its video game that improves symptoms of ADHD in children, on Wednesday announced it would reorient its business around selling its products directly to users over the counter, rather than by prescription.

In connection with the move away from prescription sales, Akili will reduce its workforce by 40%, which the company projects will extend its runway into the second half of 2025. The Boston-based company will continue offering its pediatric treatment, EndeavorRx, by prescription until it can convert it to over-the-counter labeling — it plans to submit data to FDA in 2024.

Akili went public last year and though its prescription sales were slowly increasing, the company’s costs far outstripped its revenues. In its second-quarter results reported in August, Akili said it earned just $114,000 on $15.3 million in expenses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： AI used to predict Covid

knowledge

WSS

Gene therapy denied for Afghan refugee whose father aided U.S.

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Do more moles mean more problems? Not so, says new study

Ascension's ugly legal battle over care for poor patients in Texas

Akili, maker of video game for ADHD, to be acquired for 34 million

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

hotspot

knowledge

focus

Duchenne breakthrough therapy leaves behind pioneering families

Physician assistants need a new name. Here's what it should be

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Childbirth

What does generative AI mean for health care? We asked experts

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Hepatitis C has a cure — but many Americans still lack access to it

Insmed lung disease drug hits target in key Phase 3 trial

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

hotspot

First Opinion Podcast: What happens when kids become caregivers?

Nonprofit, backed by Microsoft, to certify AI tools in health care

Akili, maker of video game for ADHD, to be acquired for 34 million

Prosthetic arm enables patients to feel the objects they grip

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

knowledge

knowledge

knowledge

leisure time